Evidence map›Paper›PMID 28498560›Full record

ArticleThe European journal of neuroscience2017

Deletion of α5 nicotine receptor subunits abolishes nicotinic aversive motivational effects in a manner that phenocopies dopamine receptor antagonism.

Taryn E Grieder, Olivier George, Mandy Yee, Michael A Bergamini, Michal Chwalek, Geith Maal-Bared, Hector Vargas-Perez, Derek van der Kooy

Open access · greenAbstract read
In one paragraph

Article in The European journal of neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. β2* nAChRs on VTA dopamine and GABA neurons separately mediate nicotine aversion and reward.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  8. Article
  9. Article
  10. Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Taryn E GriederInstitute of Medical Science, University of Toronto, 1110-160 College St, Toronto, ON, M5S 3E1, Canada.ORCID http://orcid.org/0000-0003-4282-6049
Olivier GeorgeCenter for the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA.
Mandy YeeInstitute of Medical Science, University of Toronto, 1110-160 College St, Toronto, ON, M5S 3E1, Canada.
Michael A BergaminiInstitute of Medical Science, University of Toronto, 1110-160 College St, Toronto, ON, M5S 3E1, Canada.
Michal ChwalekDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Geith Maal-BaredInstitute of Medical Science, University of Toronto, 1110-160 College St, Toronto, ON, M5S 3E1, Canada.
Hector Vargas-PerezDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Derek van der KooyInstitute of Medical Science, University of Toronto, 1110-160 College St, Toronto, ON, M5S 3E1, Canada.
University of Toronto · CAScripps Research Institute · US

Funding

Effect of Exposure to Nicotine Vapor on the Vulnerability to Nicotine DependenceR21DA036691 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI GEORGE, OLIVIER · 2014 to 2016
$530k
NIDA NIH HHS R21 DA036691
6 · The paper itself

Abstract

Nicotine addiction is a worldwide epidemic that claims millions of lives each year. Genetic deletion of α5 nicotinic acetylcholine receptor (nAChR) subunits has been associated with increased nicotine intake, however, it remains unclear whether acute nicotine is less aversive or more rewarding, and whether mice lacking the α5 nAChR subunit can experience withdrawal from chronic nicotine. We used place conditioning and conditioned taste avoidance paradigms to examine the effect of α5 subunit-containing nAChR deletion (α5 -/-) on conditioned approach and avoidance behaviour in nondependent and nicotine-dependent and -withdrawn mice, and compared these motivational effects with those elicited after dopamine receptor antagonism. We show that nondependent α5 -/- mice find low, non-motivational doses of nicotine rewarding, and do not show an aversive conditioned response or taste avoidance to higher aversive doses of nicotine. Furthermore, nicotine-dependent α5 -/- mice do not show a conditioned aversive motivational response to withdrawal from chronic nicotine, although they continue to exhibit a somatic withdrawal syndrome. These effects phenocopy those observed after dopamine receptor antagonism, but are not additive, suggesting that α5 nAChR subunits act in the same pathway as dopamine and are critical for the experience of nicotine's aversive, but not rewarding motivational effects in both a nondependent and nicotine-dependent and -withdrawn motivational state. Genetic deletion of α5 nAChR subunits leads to a behavioural phenotype that exactly matches that observed after antagonizing dopamine receptors, thus we suggest that modulation of nicotinic receptors containing α5 subunits may modify dopaminergic signalling, suggesting novel therapeutic treatments for smoking cessation.

Indexed as

MotivationPhenotypeAnimalsGene DeletionMaleMiceMice, Inbred C57BLReceptors, DopamineReceptors, NicotinicRewardTobacco Use DisorderCHRNA5 protein, mouseReceptors, DopamineReceptors, Nicotinicconditioned place preferencegenetic knockout micemotivationnicotine withdrawalventral tegmental area

Identifiers

PMID28498560
PMCPMC8162765
OpenAlexW2613413229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.